HER2-Positive Breast Cancer

April 17th 2024

Those aged 18 to 40 years with invasive, HER2-positive breast cancer showed a survival benefit from upfront surgery over neoadjuvant chemotherapy.

January 13th 2024

A Satellite Session, involving members from US Oncology, focused on treatment options for patients with HER2-positive metastatic breast cancer.

October 21st 2023

Central nervous system progression-free survival appears to be longer with trastuzumab deruxtecan than with comparator treatment in those with HER2-positive metastatic breast cancer and brain metastases.

August 31st 2023

Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.